What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
Where is Enanta Pharmaceuticals' stock going? Where will Enanta Pharmaceuticals' stock price be in 2017?
3 brokerages have issued twelve-month target prices for Enanta Pharmaceuticals' stock. Their predictions range from $26.00 to $27.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $26.50 in the next twelve months.
When will Enanta Pharmaceuticals announce their earnings?
Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.
What are analysts saying about Enanta Pharmaceuticals stock?
Here are some recent quotes from research analysts about Enanta Pharmaceuticals stock:
According to Zacks Investment Research, "Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. " (11/29/2016)
J P Morgan Chase & Co analysts commented, "Today after market close, Enanta reported F3Q financial results and provided a pipeline update. While we expect AbbVie’s Viekira Pak to remain a key driver for ENTA shares in 2016, we see the company’s wholly owned assets becoming increasingly important valuation drivers over time." (8/9/2016)
Who owns Enanta Pharmaceuticals stock?
Enanta Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.02%), State Street Corp (2.98%), FMR LLC (2.06%), Stonepine Capital Management LLC (1.22%), Armistice Capital LLC (1.20%) and Dimensional Fund Advisors LP (0.94%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathaniel S Gardiner, Paul J Mellett, Terry Vance and Yat Sun Or.
Who sold Enanta Pharmaceuticals stock? Who is selling Enanta Pharmaceuticals stock?
Enanta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Mcclain Value Management LLC, FMR LLC, GSA Capital Partners LLP and Envestnet Asset Management Inc..
Who bought Enanta Pharmaceuticals stock? Who is buying Enanta Pharmaceuticals stock?
Enanta Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Stonepine Capital Management LLC, Dimensional Fund Advisors LP, Russell Investments Group Ltd., Guggenheim Capital LLC, Two Sigma Investments LP, Armistice Capital LLC and Tudor Investment Corp Et Al. Company insiders that have bought Enanta Pharmaceuticals stock in the last two years include Nathaniel S Gardiner and Terry Vance.
How do I buy Enanta Pharmaceuticals stock?
Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Enanta Pharmaceuticals stock cost?
One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $29.17.